112 related articles for article (PubMed ID: 4851044)
1. Clinical evaluation of indoramin as the sole agent for the treatment of hypertension.
Kramer R; Rosendorff C; Bloom D
S Afr Med J; 1974 Aug; 48(37):1569-72. PubMed ID: 4851044
[No Abstract] [Full Text] [Related]
2. Clinical evaluation of indoramin, a new antihypertensive agent.
Lewis PJ; George CF; Dollery CT
Eur J Clin Pharmacol; 1973 Dec; 6(4):211-6. PubMed ID: 4359995
[No Abstract] [Full Text] [Related]
3. Proceedings: Initial clinical experience with indoramin, a new antihypertensive agent.
Royds RB
Br J Pharmacol; 1972 Feb; 44(2):379P-380P. PubMed ID: 4668635
[No Abstract] [Full Text] [Related]
4. Clinical evaluation of SE 1520 in the treatment of hypertension.
Seedat YK; Reddy J
Curr Ther Res Clin Exp; 1974 Apr; 16(4):275-80. PubMed ID: 4208341
[No Abstract] [Full Text] [Related]
5. Double blind controlled trial of indoramin in the treatment of essential hypertension.
Dollery DT; George DG; Lewis PJ
Br J Pharmacol; 1972 Nov; 46(3):542P-543P. PubMed ID: 4571183
[No Abstract] [Full Text] [Related]
6. Studies relating to the antihypertensive and antidysrhythmic action of indoramin.
Baum T; Shropshire AT; Eckfeld DK; Metz N; Dinish JL; Peters JR; Butz F; Gluckman MI
Arch Int Pharmacodyn Ther; 1973 Aug; 204(2):390-406. PubMed ID: 4356047
[No Abstract] [Full Text] [Related]
7. A double blind comparison of indoramin with clonidine in the treatment of moderate to severe essential hypertension.
Yajnik BH; Shah JS
J Assoc Physicians India; 1985 May; 33(5):339-43. PubMed ID: 3900029
[No Abstract] [Full Text] [Related]
8. Human pharmacology of indoramin.
Coltart DJ; Lockhart JD; Royds RB; Turner P
Br J Pharmacol; 1971 Oct; 43(2):467P-468P. PubMed ID: 4400576
[No Abstract] [Full Text] [Related]
9. [Indoramin, a drug with prevalent antihypertensive activity: experimental study].
Marmo E; Rossi F; Caputi AP; Lampa E; Petrarca R; Ottavo R
Clin Ter; 1979 Feb; 88(3):233-62. PubMed ID: 445975
[No Abstract] [Full Text] [Related]
10. Indoramin in the treatment of hypertension.
Stannard M; Cohen M
Practitioner; 1983 Oct; 227(1384):1601-5. PubMed ID: 6634630
[No Abstract] [Full Text] [Related]
11. Comparison of indoramin and methyldopa in hypertension.
Rosendorff C
S Afr Med J; 1976 May; 50(20):764-8. PubMed ID: 779054
[TBL] [Abstract][Full Text] [Related]
12. Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: a double-blind multicentre study. The Multicentre Study Group on Treatment Association with Perindopril.
Letellier P; Overlack A; Agnes E; Desche P
J Hum Hypertens; 1994 Feb; 8(2):145-9. PubMed ID: 8207741
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of indoramin added to oxprenolol and bendrofluazide as a third agent in severe hypertension.
Marshall AJ; Kettle MA; Barritt DW
Br J Clin Pharmacol; 1980 Sep; 10(3):217-21. PubMed ID: 7437237
[TBL] [Abstract][Full Text] [Related]
14. [24-hour effect and tolerance for perindopril (Prestarium) in mild and moderate essential hypertension].
Widimský J; Cihák R; Fedelesová V; Lefflerová K; Mayer O; Uhlír O
Vnitr Lek; 1992 Nov; 38(11):1066-71. PubMed ID: 1494869
[TBL] [Abstract][Full Text] [Related]
15. Effects of perindopril on glucose and lipid metabolism in patients with mild-to-moderate essential hypertension and glucose intolerance.
Uchida K; Azukizawa S; Kigoshi T; Nakano S; Kaneko M; Morimoto S; Matsui A
Clin Ther; 1994; 16(3):466-70. PubMed ID: 7923313
[TBL] [Abstract][Full Text] [Related]
16. Some clinical pharmacological studies with indoramin, with observations on its therapeutic usefulness.
de White C; Royds RB; Turner P
Postgrad Med J; 1974 Dec; 50(590):729-33. PubMed ID: 4469040
[TBL] [Abstract][Full Text] [Related]
17. Proceedings: Haemodynamic effects of indoramin: a non-invasive technique for the cardiovascular evaluation of drugs.
Coltart DJ; Royds RB
Br J Pharmacol; 1972 Feb; 44(2):387P-388P. PubMed ID: 4668640
[No Abstract] [Full Text] [Related]
18. Clinical safety and effectiveness of indorenate in essential hypertension.
Huape-Arreola S; Herrera-Abarca JE; Ruiz-Vega H; Hong E
Proc West Pharmacol Soc; 2002; 45():197-8. PubMed ID: 12434580
[No Abstract] [Full Text] [Related]
19. Antihypertensive therapy with indoramin: risk-benefit profile in clinical practice.
Stannard M; Cohen M; Marrott PK; Pascucci VL
J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S48-52. PubMed ID: 2423797
[TBL] [Abstract][Full Text] [Related]
20. The effect of parenteral indoramin on peripheral blood flow in patients with Raynaud's disease or atherosclerosis associated with intermittent claudication.
Fares CM; Milliken JC
Curr Med Res Opin; 1974; 2(2):57-62. PubMed ID: 4151332
[No Abstract] [Full Text] [Related]
[Next] [New Search]
